ELITE Extension Data and What Happened After the Trial Ended

At a glance

| Parameter | Detail | |---|---| | Trial | ELITE (Early versus Late Intervention Trial with Estradiol) | | N | 643 postmenopausal women | | Intervention | Oral 17β-estradiol 1 mg/day (± vaginal progesterone gel) | | Comparator | Placebo | | Duration | Median 5 years (range 2.5 to 6.7 years) | | Primary endpoint | Rate of change in carotid artery intima-media thickness (CIMT) | | Key result | CIMT progression significantly slower in the early-postmenopause stratum (within 6 years of menopause) vs. placebo; no benefit in the late-postmenopause stratum (≥10 years) |

Why Extension Data Matters Here

The ELITE trial was designed to test one specific question: does the timing of hormone therapy initiation determine whether estradiol protects against subclinical atherosclerosis? It answered that question clearly. Women who began oral estradiol within 6 years of menopause had significantly less CIMT progression than those on placebo (mean difference in CIMT rate of change: −0.0034 mm/year, p = 0.008). Women who started ≥10 years after menopause showed no such benefit.

But the trial was not designed to answer what happens next. Does CIMT stabilization persist after stopping estradiol? Does the vascular benefit translate into fewer heart attacks and strokes over 10 or 15 years? Does the early-group advantage widen, hold steady, or vanish? These are the questions clinicians and patients actually face when deciding about duration of therapy, and the original ELITE publication could not address them within its 5-year window.

What Formal Follow-Up Exists

ELITE did not include a pre-specified extension phase. Unlike KEEPS (Kronos Early Estrogen Prevention Study), which published a 4-year post-intervention follow-up in 2019, the ELITE investigators have not published a structured post-trial assessment of participants. This is one of the most significant gaps in the timing-hypothesis evidence base.

Several factors explain this absence. ELITE was funded primarily through NIH grants (R01 AG-024154), and securing additional funding for an observational extension is a separate, competitive process. Participants were free to continue, switch to, or discontinue hormone therapy at their own discretion once the trial ended. Without controlled post-trial treatment assignment, any follow-up analysis introduces confounding by indication: women who felt well on estradiol were more likely to continue, while those with side effects stopped.

The ELITE investigators did conduct secondary imaging analyses, including cardiac CT for coronary artery calcium (CAC), published alongside the primary CIMT results. In the early-postmenopause group, CAC scores did not differ between estradiol and placebo, a discrepancy that generated debate about whether CIMT and CAC measure the same vascular process or respond differently to estrogen exposure.

Lessons from Parallel Trials That Did Follow Up

KEEPS Follow-Up

The KEEPS trial follow-up data examined 727 recently menopausal women (age 42, 58) originally randomized to oral conjugated equine estrogens, transdermal estradiol, or placebo for 4 years. At the 3-year post-treatment reassessment, the modest CIMT benefit observed during active therapy had disappeared. CIMT progression rates converged across all three groups within 2 to 3 years of stopping therapy.

This finding has direct relevance to ELITE. If the biological mechanism is suppression of inflammatory-mediated intimal thickening rather than structural arterial remodeling, then the effect would be expected to attenuate once estrogen levels drop. The KEEPS post-trial data support this "suppression, not reversal" model.

WHI Long-Term Follow-Up

The Women's Health Initiative 18-year cumulative follow-up offers the longest post-trial data on HRT and cardiovascular outcomes. Among women aged 50, 59 at randomization (the age range most analogous to ELITE's early-postmenopause group), conjugated equine estrogens alone showed a trend toward lower coronary heart disease mortality during the intervention phase that did not persist in the post-intervention period. All-cause mortality did not differ significantly between hormone and placebo groups during cumulative 18-year follow-up.

The WHI results are not directly comparable to ELITE because the WHI used conjugated equine estrogens rather than 17β-estradiol, and the study population was older on average. But the pattern, where vascular benefit during therapy does not translate into lasting mortality reduction after cessation, is consistent across multiple trials and reinforces the concern about durability.

Regression to the Mean: A Methodological Concern

One criticism raised after ELITE's publication was whether the CIMT difference in the early group could reflect regression to the mean rather than a true treatment effect. CIMT measurement has inherent variability (coefficient of variation 3 to 5% across readings), and women selected for "early" postmenopausal status may have had slightly different baseline CIMT distributions than the late group.

The ELITE investigators addressed this partly through their statistical model, which used rate of change (slope) rather than absolute CIMT values at endpoint. Slope-based analysis is less susceptible to regression to the mean than pre-post difference methods. The trial also used B-mode ultrasound of the right common carotid artery far wall, a measurement site chosen for reproducibility per American Society of Echocardiography guidelines.

Still, without post-trial repeat imaging, it is impossible to determine whether the divergent CIMT slopes in ELITE's early group remained divergent, converged (as in KEEPS), or even reversed after estradiol cessation.

Safety Signals During and After the Trial

On-Trial Safety

During the ELITE trial, oral estradiol was well tolerated. There were no significant differences in rates of breast cancer, venous thromboembolism, or stroke between estradiol and placebo in either the early or late stratum. However, the trial was not powered for clinical events. With only 643 participants over a median 5 years, event rates were too low to detect meaningful differences in these outcomes.

Post-Trial Safety Context

Long-term safety data for oral 17β-estradiol come primarily from observational registries and the FDA-approved prescribing information for estradiol, which carries boxed warnings for endometrial cancer (when used without a progestogen), cardiovascular events, and breast cancer based largely on WHI-era data.

The 2022 Menopause Society position statement notes that for women under 60 or within 10 years of menopause, the benefit-risk profile of hormone therapy is generally favorable, consistent with ELITE's timing hypothesis. But this endorsement applies to the symptomatic treatment window, not to indefinite cardiovascular prevention. No major guideline currently recommends initiating or continuing HRT solely for cardioprotection based on ELITE or similar data.

What ELITE Cannot Tell Us About Hard Outcomes

ELITE used CIMT as a surrogate endpoint. CIMT is a validated predictor of cardiovascular events at the population level: a 2007 meta-analysis of individual patient data showed that each 0.1 mm increase in common carotid IMT is associated with a 10 to 15% increase in myocardial infarction risk and a 13 to 18% increase in stroke risk. But surrogate endpoints do not always predict clinical benefit from intervention. The discordance between CIMT and CAC results within ELITE itself is one example. Another is the broader lesson from statin trials, where CIMT reduction with some agents did not always correspond to event reduction.

Without a clinical-event extension, the most ELITE can claim is that early-initiation estradiol slows one measure of subclinical atherosclerosis. Whether this translates into fewer heart attacks, strokes, or cardiovascular deaths remains unproven for oral 17β-estradiol specifically.

What Clinicians Should Take from the Post-Trial Picture

The composite picture from ELITE, KEEPS follow-up, and WHI long-term data supports several clinical inferences:

| Question | Best Available Answer | |---|---| | Does early HRT slow atherosclerosis? | Yes, based on CIMT in ELITE and KEEPS | | Does the benefit persist after stopping? | Probably not, based on KEEPS follow-up | | Does the CIMT effect reduce heart attacks? | Unproven for 17β-estradiol; WHI follow-up found no lasting mortality reduction | | Should HRT be prescribed solely for cardioprotection? | No major guideline recommends this | | Is early-start HRT safe for symptomatic women? | Yes, per 2022 Menopause Society guidance for women <60 or within 10 years of menopause |

The clinical bottom line: ELITE strengthened the timing hypothesis but did not close it. The absence of extension data is not a minor gap. It is the missing chapter that would determine whether the timing hypothesis changes practice or remains a physiological observation.

Ongoing and Planned Research

As of 2025, no registered trial on ClinicalTrials.gov specifically extends the ELITE cohort. The REPLENISH trial and other studies of estradiol-progestogen combinations have addressed symptom relief and endometrial safety but not the timing-hypothesis question with clinical endpoints. A definitive answer would require a large, event-driven trial randomizing recently menopausal women to estradiol vs. placebo for 10+ years with cardiovascular events as the primary outcome, a study that remains unfunded and logistically challenging.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221-1231. PubMed
2. Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial (KEEPS follow-up). Ann Intern Med. 2019;171(2):86-95. PubMed
3. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA. 2017;318(10):927-938. PubMed
4. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. PubMed
5. Estradiol prescribing information. U.S. Food and Drug Administration. FDA Label
6. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115(4):459-467. PubMed
7. Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk. J Am Soc Echocardiogr. 2008;21(2):93-111. PubMed